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Abstract: Simian hemorrhagic fever virus (SHFV) causes a fulminant and typically lethal viral
hemorrhagic fever (VHF) in macaques (Cercopithecinae: Macaca spp.) but causes subclinical infections
in patas monkeys (Cercopithecinae: Erythrocebus patas). This difference in disease course offers a
unique opportunity to compare host responses to infection by a VHF-causing virus in biologically
similar susceptible and refractory animals. Patas and rhesus monkeys were inoculated side-by-side
with SHFV. Unlike the severe disease observed in rhesus monkeys, patas monkeys developed a
limited clinical disease characterized by changes in complete blood counts, serum chemistries, and
development of lymphadenopathy. Viral RNA was measurable in circulating blood 2 days after
exposure, and its duration varied by species. Infectious virus was detected in terminal tissues of
both patas and rhesus monkeys. Varying degrees of overlap in changes in serum concentrations of
interferon (IFN)-γ, monocyte chemoattractant protein (MCP)-1, and interleukin (IL)-6 were observed
between patas and rhesus monkeys, suggesting the presence of common and species-specific cytokine
responses to infection. Similarly, quantitative immunohistochemistry of livers from terminal monkeys
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and whole blood flow cytometry revealed varying degrees of overlap in changes in macrophages,
natural killer cells, and T-cells. The unexpected degree of overlap in host response suggests that
relatively small subsets of a host’s response to infection may be responsible for driving hemorrhagic
fever pathogenesis. Furthermore, comparative SHFV infection in patas and rhesus monkeys offers an
experimental model to characterize host–response mechanisms associated with viral hemorrhagic
fever and evaluate pan-viral hemorrhagic fever countermeasures.
Keywords: Arteriviridae; arterivirus; host response; macaque; patas monkey; pathogenesis; SHFV;
simarterivirus; simian hemorrhagic fever; viral hemorrhagic fever
1. Introduction
Viral hemorrhagic fevers (VHFs) are primarily caused by single-stranded RNA viruses [1].
VHF is a broadly defined syndrome: fever, hepatic and renal complications, large increases in
proinflammatory cytokines, and coagulopathy are common features [2,3]. Simian hemorrhagic fever
virus (SHFV) is a positive-sense, single-stranded RNA virus classified in the family Arteriviridae,
which also includes equine arteritis virus and porcine reproductive and respiratory syndrome viruses
1 and 2 [4,5]. In addition to SHFV, several other simian arteriviruses (subfamily Simarterivirinae)
have been identified [6–8]. Among simarteriviruses, SHFV, simian hemorrhagic encephalitis virus
(SHEV), and Pebjah virus (PBJV) are known to cause severe disease in Asian macaques of various
species [9]. Kibale red colobus virus 1 (KRCV-1) was found to cause a self-limiting disease in crab-eating
macaques (Macaca fascicularis) [10]. It is not known whether the other identified simarteriviruses infect
or cause disease in macaques or their natural hosts. Here, and in combination with an article by
Buechler et al. [11], we examine infection of natural hosts (patas monkeys [Erythrocebus patas] and olive
baboons [Papio anubis]) of simarteriviruses and compare disease course of these simarteriviruses in
rhesus monkeys (Macaca mulatta).
SHFV was discovered during a VHF outbreak of simian hemorrhagic fever (SHF) in National
Institutes of Health (NIH) animal facilities in the United States in 1964 [12]. Transmission during the
NIH SHF outbreak is thought to have occurred through tattooing needles used on both macaques and
co-housed African primates [12]. The virus is highly virulent in rhesus monkeys, crab-eating macaques,
stump-tailed macaques (Macaca arctoides), and Japanese macaques (Macaca fuscata), but SHFV is
suspected to cause little to no disease in African primates such as patas monkeys or baboons [11–14].
SHFV infection in macaques mirrors aspects of human VHFs, such as Ebola virus disease, by inducing
fever, edema, coagulopathy, hepatocellular degeneration and necrosis, and elevated inflammatory
cytokine concentrations [13–15]. Like all VHFs, SHF is thought to be driven by a dysregulated host
response leading to a dysregulated immune response and poor viral clearance [13,14,16].
Studying SHF offers a unique opportunity to compare infection and associated responses in
refractory and highly susceptible primates that are biologically similar to each other and to humans.
Some hemorrhagic fever-causing viruses naturally infect non-primate mammals that may serve as hosts
or reservoirs. For instance, Marburg virus and Ravn virus (Filoviridae: Marburgvirus) naturally circulate
in Egyptian rousettes (Rousettus aegyptiacus), in which they do not cause disease, whereas these viruses
cause frequently lethal disease experimentally in primates and naturally in humans [17]. Similarly,
arenaviruses associated with human VHFs, such as Machupo virus and Lassa virus (Arenaviridae:
Mammarenavirus), subclinically infect distinct rodent reservoir hosts [18,19]. Comparing the response
to infection between refractory hosts, preferably the reservoirs themselves, and susceptible hosts
may offer significant insight into responses involved in VHF pathogenesis. For most hemorrhagic
fever-causing viruses, comparisons between refractory and susceptible animals during infection is
confounded by large biological differences. For example, work with pathogenic mammarenaviruses
has demonstrated that mechanisms present in murine hosts, even susceptible ones, are fundamentally
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different than those of primates [20]. Unlike these examples, SHFV infects biologically similar refractory
and susceptible animals and may provide a path towards meaningful interspecies comparisons of
responses to hemorrhagic fever-causing virus infection.
The goal of this work was to compare host responses in biologically similar nonhuman primates,
patas (refractory) monkeys and rhesus (susceptible) monkeys, infected with SHFV to identify factors
associated with differential outcomes to infection. The findings are the first in-depth characterization
of SHFV infection in patas monkeys and confirm that patas monkeys are largely unaffected by SHFV
infection. Our work demonstrates that, although patas and rhesus monkeys develop drastically
different diseases, the host responses to infection overlap, and suggest that VHF pathogenesis may be
initiated by relatively small perturbations to the host’s response to infection.
2. Materials and Methods
2.1. Cells and Virus
Simian hemorrhagic fever virus (SHFV; Nidovirales: Arteriviridae: Simarterivirinae: Deltaarterivirus)
strain LVR42-0/M6941 [21] was passaged twice before a final passage on MA-104 cells to create the
virus stock. Briefly, the virus stock was prepared by freeze-thawing infected cells three times prior to
clarification with low-speed centrifugation and was then concentrated by centrifugation at 16,000× g.
The pellets were resuspended in PBS and combined. The final viral stock was sequenced as in [22] for
quality control purposes (GenBank #MH155201). Sequencing confirmed the expected genotype and
lack of any contamination.
2.2. Animals
Six patas monkeys (4 females and 2 males) and 6 rhesus monkeys (3 females and 3 males) were
used in this study. The patas monkeys ranged from 5.51–14.01 kg in weight and 9–14 years in age,
whereas rhesus monkeys ranged from 4.77–12.75 kg in weight and 8–12 years in age. Rhesus monkeys
were obtained from the National Institute of Allergy and Infectious Disease (NIH/NIAID) rhesus
monkey colony. The patas monkeys were obtained from the National Institute of Child Health and
Human Development (NIH/NICHD). The subjects were screened for simian T-lymphotrophic virus,
simian immunodeficiency virus, and simian retrovirus infections and cleared for use in the experiment
by the facility veterinarian. The patas monkeys were determined to be serologically negative for SHFV
prior to enrollment. The rhesus monkeys were obtained from a SHFV-free source, and, therefore, were
not screened prior to use in this experiment. The subjects were randomly assigned to 4 groups (2 groups
of patas monkeys, inoculated and mock-inoculated, and 2 groups of rhesus monkeys, inoculated and
mock-inoculated), for sex, age and weight. The animals of 1 group of patas monkeys and 1 group of
rhesus monkeys each received 5000 PFU of SHFV diluted in 1 mL of phosphate-buffered saline (PBS),
whereas the animals of the remaining groups each received 1 mL of PBS (mock) by intramuscular
injection of the right quadriceps. The subjects were housed in separate rooms and had access to food
and water ad libitum.
The subjects were monitored at least twice daily. Physical exams were performed on pre-determined
experimental days (−9, −6, 0, 2, 4, 6, 8, 10, 12, 15, 19, and 21) and prior to euthanasia. Blood was
collected on all the physical exam days, except day 0, and prior to euthanasia. The scheduled days for
euthanasia with necropsy were as follows: mock-inoculated patas monkeys at 19 days post-inoculation
(PI), SHFV-inoculated patas monkeys at 21 days post-inoculation and SHFV-inoculated rhesus monkeys
at 20 days post-inoculation. Mock-inoculated rhesus monkeys were euthanized and underwent
complete necropsies at 10 days post-inoculation as SHFV-inoculated rhesus monkeys typically succumb
on or around day 10 PI [13]. The staggering of planned euthanasia days was logistically necessary
to ensure safe working conditions in biosafety level 4 (BSL-4) working environments. The subjects
were euthanized at scheduled times or upon reaching pre-established clinical endpoint criteria (score).
The clinical score was assessed across 5 categories (overall clinical appearance, respiratory function,
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responsiveness, and core body temperature) with a score of 0 (normal) to 10 (most severe disease).
If the total score for all 5 categories, or the score of any 1 category, was 10 or greater, then the animal
was euthanized. At euthanasia, the subjects were perfused with saline before necropsy and sample
collection. The subjects were housed in an Association for Assessment and Accreditation of Laboratory
Animal Care (AAALAC) International-accredited facility under BSL-4 conditions. All the experimental
procedures were approved by the NIAID Division of Clinical Research (DCR), Animal Care and Use
Committee and were performed in compliance with the Animal Welfare Act regulations, Public Health
Service policy, and the Guide for the Care and Use of Laboratory Animals recommendations.
2.3. Virus Quantification
Virus stock and tissue concentrations were determined by plaque assay on grivet (Chlorocebus
aethiops) kidney epithelial MA-104 cells (ATCC, Manassas, VA, USA). Briefly, serial dilutions of 10%
(w/v) tissue homogenates were added to the cell monolayers and incubated for 1 h. Then, the
monolayers were overlaid with 0.8% tragacanth (Sigma, St. Louis, MO, USA), minimal essential
medium (Lonza, Walkersville, MD, USA), 1% penicillin–streptomycin (Lonza, Basel, Switzerland),
and 2% heat-inactivated fetal bovine serum (Sigma, St. Louis, MO, USA) final concentration. After a
3-day incubation period, the overlays were aspirated, and the monolayers were fixed using 10%
neutral-buffered formalin (Fisher Scientific, Hampton, TN, USA) with 0.2% crystal violet (Ricca,
Arlington, TC, USA) prior to enumeration.
2.4. Plasma Cytokines
The plasma concentrations of granulocyte-macrophage colony stimulating factor (GM-CSF),
interferon gamma (IFN-γ), monocyte chemoattractant protein 1 (MCP-1), and interleukins (IL)-2, -4, -6,
-8, -10, and -17 were measured using a Milliplex non-human primate kit (MilliporeSigma, St. Louis,
MO, USA) as described previously [13]. The upper and lower limits of quantification (ULOQ and
LLOQ) were determined for each analyte from the standards included with the kit.
2.5. Hematology
Complete blood counts (Sysmex XS1000i, Lincolnshire, IL, USA) and selected serum chemistries
(Piccolo General Chemistry 13 kits, Abaxis, Union City, CA, USA), were performed at the indicated
timepoints using blood collected in K3 EDTA and SST tubes (BD, San Jose, CA, USA). Due to a lack
of published data, the standard ranges of hematologic parameters and serum chemistries for patas
monkeys were defined as the mean +/– two standard deviations of all pre-exposure timepoints.
The standard ranges for rhesus monkeys were determined from data kept by veterinary staff on
subjects housed in the facility.
2.6. Histology, In Situ Hybridization, and Immunohistochemistry
Formalin-fixed paraffin-embedded (FFPE) animal tissue sections (5-µm) were used for
immunohistochemical staining using the following antibodies: NKG2A (Abcam, Cambridge, MA,
USA); Iba1 (Wako, Richmond, VA, USA); MHC1 [Clone EPR1394Y] (Abcam); CD8 (Abcam); and CD3
[Clone 12] (AbD, Serotec Hercules, CA, USA). Staining was performed on the Bond RX platform
(Leica Biosystems, Wetzlar, Germany) according to the manufacturer’s protocol. Briefly, sections were
baked, deparaffinized, and rehydrated. Epitope retrieval was performed using Leica Epitope Retrieval
Solution 1, pH 6.0, heated to 100 ◦C for 20 min and quenched with hydrogen peroxide prior to the
addition of primary antibody. The Bond Polymer Refine Detection kit (Leica Biosystems) was used for
chromogen detection. Image analysis was performed on select tissues from all groups to quantify the
degree of positive staining. Images were obtained on a bright-field Leica Aperio AT2 slide scanner
(Leica Biosystems) and processed using Aperio Image Scope (v12.3) algorithms. For quantification,
images of the entire slide were used to prevent sampling bias. The Positive Pixel Count Algorithm was
used to assign pixels to intensity ranges of positive (strong (nsp), medium (np), and weak (nwp)) and
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negative (nn) pixels. The pixels were categorized, and a positive percentage was calculated per image




× 100 = nsp(
nsp + np + nwp + nn
) × 100 (1)
After a percentage of positive pixels per slide was obtained for each subject and marker, values
were averaged by group, and the significance was assessed in Excel using the T.TEST function. SHFV
RNA RNAscope in situ hybridization (ISH) was performed as previously described [23].
2.7. Electron Microscopy
Electron microscopy samples were processed and imaged as previously reported [24].
2.8. Whole Blood Viral RNA qPCR
Monkey peripheral blood samples were inactivated in 3 volumes of Trizol LS buffer (Thermo
Fisher Scientific, Waltham, MA, USA). RNA was extracted using the Qiagen AllPrep 96 kit as described
by manufacturer (Qiagen, Valencia, CA, USA) except that each sample was treated with 27 units
of DNAse I (Qiagen). The SHFV RNA copy number was determined by RT–qPCR using primers
and probes targeting the SHFV gp15 gene. The AgPath-ID One-Step RT–PCR kit (Thermo Fisher
Scientific) was used to perform the assay. The primers and Cal Fluor Orange 560/BHQ1-labeled
probe were synthetized by LCG Biosearch Technologies (Petaluma, CA, USA). The RT–qPCR reactions
were performed in 20 µL reactions using forward primer (5’-CGACCTCCGAGTTGTTCTACCT-3’),
reverse primer (5’-GCCTCCGTTGTCGTAGTACCT-3’), and fluorescent probe (5’-CCCACCTCAGC
ACACATCAAACAGCT-3’). Synthetic DNA (5’-TTTCGCCGAACCCGGCGACCTCCGAGTTGTT
CTACCTGGTCCCACCTCAGCACACATCAAACAGCTGCTGATCAGGTACTACGACAACGGAGG
CGGAAATCTTTCATATG-3’; LCG Biosearch Technologies, Novato, CA, USA) was used as a standard.
The qPCR reactions were run at 50 ◦C for 10 min, 95 ◦C for 10 min, 55 cycles of 95 ◦C for 15 s, and 60 ◦C
for 45 s on a 7900HT Fast Real-Time PCR System (Thermo Fisher Scientific). The data were analyzed
using Applied Biosystems 7900HT Fast Real-Time PCR System Software (Thermo Fisher Scientific).
2.9. Flow Cytometry
Whole blood was assessed for the following markers: HLA-DR-FITC (BioLegend, San Diego,
CA, USA), CD16-APC (BD), PD-1-APC-Cy7 (BioLegend, San Diego, CA, USA), CD3-AF700
(BD), CD11c-PE (BD), CD28-PE-Cy5 (BioLegend), NKG2a-PE-Cy7 (Beckman Coulter, Brea CA,
USA), CD163-PE/Dazzle594 (BioLegend), CD4-BV421 (BD), CD14-BV510 (BioLegend), CD20-BV570
(BioLegend), CD8a-BV605 (BD), CD123-BV650 (BD), PD-L1-BV711 (BioLegend), CD95-BV785
(BioLegend), and Ki-67-PerCP-Cy5.5 (BD). Briefly, 100 µL of whole blood was incubated with 100 µL
of the marker panel (excluding Ki-67) and incubated for 20 min. The red blood cells were lysed
with 1 mL of BD FACSLyse (BD) for 10 min. The cells were washed and fixed for 30 min using BD
Cytofix/Cytoperm (BD) and incubated with Ki-67 antibody for 30 min at 4 ◦C, followed by a final
wash in 1× BD Permwash (BD). Data acquisition and analysis was performed with FlowJo version
10.2 (BD). During the acquisition and analysis, species-specific patterns of cell phenotypes were taken
into consideration [25]. After filtering for single cell events and removing granulocytes, immune cell
populations were assessed according to the features listed in Table 1.
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Table 1. Flow cytometry gating strategy.
Leukocyte Subset Phenotype
T Cells NOT Granulocytes, CD3+
CD4+ T Cells CD3+, CD4+
CD4+ Naive CD3+, CD4+, CD28+, CD95−
CD4+ Central Memory CD3+, CD4+, CD28+, CD95+
CD4+ Effector Memory CD3+, CD4+, CD28−, CD95+
CD8+ Cells CD3+, CD8+
CD8+ Naive CD3+, CD8+, CD28+, CD95−
CD8 Central Memory CD3+, CD8+, CD28+, CD95+
CD8 Effector Memory CD3+, CD8+, CD28−, CD95+
B Cells CD20+
CD14+ Monocytes HLA-DR+, CD14+, CD163−
CD14+CD163+ Macrophages HLA-DR+, CD14+, CD163+
CD14+CD163+ Macrophages HLA-DR+, CD14−, CD163+
Myeloid Dendritic Cells (mDCs) HLA-DR+, CD14−, CD163−, CD11c+, CD123−
Plasmacytoid Dendritic Cells (pDCs) HLA-DR+, CD14−, CD163−, CD11c−, CD123+
Natural Killer Cells (NK) HLA-DR−, CD3−, CD20−, SSClow, CD8+
2.10. Statistical Analysis
Statistical analyses were performed using Microsoft Excel with the T.TEST function. The significance
was defined as a p-value of less than 0.05.
2.11. Enzyme-Linked Immunosorbent Assays
The lysates from MA-104 cells infected with SHVF or mock infected (media only) were used
as substrates. The Immulon 2 HB microplates (Thermo Fisher Scientific, Walkersville, MD, USA)
were coated with cell lysates diluted in PBS and incubated overnight at 4 ◦C. The plates were then
washed five times with wash buffer comprised of PBS/0.2% Tween 20 and blocked for 2 h at room
temperature with 5% nonfat milk (LabScientific, Highlands, NJ, USA) dissolved in PBS. The plates
were then washed five times with wash buffer, and the analyte serum was diluted at 1:50 in PBS/2.5%
milk/0.05% Tween 20 was added in duplicate to the corresponding wells. After a 1-h incubation at
room temperature, the plates were washed, and horseradish peroxidase-conjugated anti-monkey IgG
(Sigma Aldrich, St. Louis, MO, USA; A2054) was added. The plates were then incubated for 1 h at room
temperature before washing with wash buffer and adding TMB Substrate (Thermo Fisher Scientific,
Walkersville, MD, USA). Following a 10-min incubation, 100 µL of TMB stop solution (Thermo Fisher
Scientific, Walkersville, MD, USA) was added to each well, and the plates were read on a SpectraMax
Plus 384 plate reader (Molecular Devices, Sunnyvale, CA, USA) at 450 nm.
3. Results
3.1. Simian Hemorrhagic Fever Virus (SHFV) Infection Results in Mild Clinical Disease in Patas Monkeys
Twelve monkeys were grouped by species into SHFV-inoculated and PBS-inoculated groups, with
three animals per group. Inoculations were 1-mL intramuscular injections in the right quadriceps
with either 5000 PFU of SHFV-LVR or PBS. The three SHFV-inoculated patas monkeys developed
axillary and inguinal lymphadenopathy starting on day 10 PI that persisted until the conclusion
of the experiment at 21 days PI. The three SHFV-inoculated rhesus monkeys developed severe
disease. Two subjects (“non-survivors”) met clinical endpoint criteria and were euthanized on
days 8 and 11 PI, respectively. The third subject (“survivor”) survived until the conclusion of the
experiment (day 20 PI). Signs of disease were first detectable on day 4 PI in SHFV-inoculated rhesus
monkeys. They developed a range of clinical signs including gingival bleeding (1/3 subjects), inguinal
lymphadenopathy (1/3), and axillary lymphadenopathy (2/3). All the SHFV-inoculated rhesus
monkeys developed petechial rashes and axial and inguinal lymphadenopathy by their respective
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endpoints. All three SHFV-inoculated rhesus monkeys developed tremors and motor dysfunction by
day 6 PI that remained until each subject’s respective endpoint. The non-surviving rhesus monkeys
developed facial edema that began on day 8 PI that persisted to their respective endpoints. The
surviving SHFV-inoculated rhesus monkey developed facial edema that began on day 12 PI and
resolved by day 16 PI. All mock-inoculated rhesus monkeys appeared clinically normal and displayed
no outward signs of disease throughout the experiment. Animal body weight remained within normal
limits for all subjects during the experiment.
3.2. SHFV Infection Results in Clinical Pathology Changes in Patas and Rhesus Monkeys
Indicated serum chemistry analytes were selected to assess organ function and other physiological
functions during SHFV infection. In SHFV-inoculated patas monkeys, alanine aminotransferase
(ALT, day 4 PI), alkaline phosphatase (ALP, days 6–12 PI) and aspartate aminotransferase (AST,
days 6–19 PI) concentrations were significantly elevated on the indicated days (Figure 1A–C).
γ-glutamyl transferase (GGT) concentrations remained normal in all SHFV-inoculated patas monkeys
(Figure 1D). SHFV-inoculated rhesus monkeys showed similar trends as patas monkeys except that
GGT concentrations were elevated on days 8 and 10 PI. ALP, AST, and GGT concentrations remained
elevated in the surviving SHFV-inoculated rhesus monkey until the conclusion of the experiment,
whereas ALT returned to baseline concentrations. Although changes in serum chemistries were
observed in all SHFV-inoculated subjects, the values did not reach concentrations suggestive of a
severe clinical disease. All subjects experienced decreases in albumin concentration coinciding with an
increase in globulin concentrations (Figure 1F) on days 8–19 and days 8 and 10 PI in SHFV-inoculated
patas and rhesus monkeys, respectively. Reticulocyte counts decreased in both SHFV-inoculated
patas (days 6 and 8 PI) and rhesus monkeys (days 2–10 PI) (Figure 1E) but did not drop below
the normal range. Hematocrit (HCT) remained normal in all subjects except for the surviving
SHFV-inoculated rhesus where HCT decreased starting on day 10 PI with anemia persisting to study
end (Figure 1G). Albumin concentrations (Figure 1H) were significantly decreased on day 19 PI in
SHFV-inoculated patas monkeys. In SHFV-inoculated rhesus monkeys, albumin concentrations were
significantly decreased on days 8 and 10 PI. No significant changes in serum chemistry were observed
in mock-inoculated patas and rhesus monkeys.
The complete blood counts revealed minor decreases in the lymphocyte numbers early in all
SHFV-inoculated patas and rhesus monkeys (days 2 and 2–4 PI, respectively), and were elevated
in SHFV-inoculated patas monkeys on days 12 and 19 respectively (Figure 1I). The monocyte
counts decreased slightly in all SHFV-inoculated patas and rhesus monkeys (days 2, 6 and day 2
PI, respectively) (Figure 1J). In SHFV-inoculated patas monkeys, the monocyte counts were elevated
on days 10 and 12 PI. No significant changes were observed in the complete blood counts in any
mock-inoculated subject.
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Figure 1. Clinical pathology changes during simian hemorrhagic fever virus (SHFV) infection.
Alanine aminotransferase (A), alkaline phosphatase (B), aspartate aminotransferase (C), gamma-
glutamyltransferase (D), reticulocyte number (E), globulin (F), hematocrit (HCT) (G), albumin (H),
lymphocyte number (I), monocyte number (J) values for patas monkeys (orange lines) and rhesus
monkeys (blue lines) either inoculated with 5,000 PFU of SHFV (closed symbols) or with PBS (open
symbols). The shaded regions represent the standard range of all pre-exposure values for the patas
monkeys or previously collected values for the rhesus monkeys. The data represent the means of
each group. The error bars represent standard deviation. * symbols represent p < 0.05 and are colored
according to species.
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3.3. SHFV Infection Results in Clinical Pathology Changes in Patas and Rhesus Monkeys
Gross examination of SHFV-inoculated patas monkeys during necropsy revealed no remarkable
findings. Non-surviving SHFV-inoculated rhesus monkeys had marked hepatosplenomegaly: the
hepatic tissues were friable and firm. Moderate peripheral and visceral lymphadenopathy were
found in both non-surviving rhesus monkeys, whereas moderate peripheral lymphadenopathy was
the only significant finding in the surviving rhesus monkey. The kidneys of one non-surviving
SHFV-inoculated rhesus monkey contained multiple infarctions with severe renal hemorrhage and
necrosis. No significant gross lesions were observed in either mock-inoculated group.
The histopathological examination (Figure 2A,B) of the spleen in SHFV-inoculated patas monkeys
revealed abundant plasma cells in one subject. The spleens of the two remaining SHFV-inoculated
patas monkeys were within normal limits. The livers of two SHFV-inoculated patas monkeys showed
inflammatory changes, whereas the third was normal. Hyperplasia was evident in the inguinal lymph
nodes of one SHFV-inoculated patas monkey. The spleens of SHFV-inoculated rhesus monkeys were
different in each subject. In the two non-survivors, one was congested, whereas fibrin deposition
was evident in the other. The spleen of the surviving subject exhibited changes that were consistent
with reactive lymphoid hyperplasia, characterized by diffuse expansion and proliferation of B-cells
at the margins of each follicle. Each of the livers of SHFV-inoculated rhesus monkeys were also
histologically different. In the survivor, perivascular inflammation with multifocal areas of necrosis
were evident. The major finding in the liver of one non-survivor was vacuolated hepatocytes, whereas
rare thrombi were the major observation in the remaining non-survivor. Hyperplasia was present in the
inguinal lymph nodes of all three SHFV-inoculated rhesus monkeys. The tissues of all mock-inoculated
subjects were normal apart from vascular congestion in two patas monkey spleens. While all three
SHFV-inoculated rhesus monkeys had neurological signs, on histopathological examination, CNS
tissues did not reveal any evidence of vasculitis or other changes that would suggest encephalitis.
The CNS tissues of all mock-inoculated animals and SHFV-inoculated patas monkeys were found to
be within normal histologic limits. Upon histopathological examination, the kidneys of all subjects
appeared to be within normal histologic limits.
Immunohistochemical staining (Figure 3) used to detect macrophages expressing ionized
calcium-binding adaptor 1 (Iba1) revealed morphologically-normal macrophages in the livers of
all three SHFV-inoculated patas monkeys. In contrast, the livers of all three SHFV-inoculated rhesus
monkeys contained macrophages that were often rounded and contained a diffusely vacuolated
cytoplasm. These changes in macrophage morphology were in direct contrast to those cells in infected
patas monkeys, which often exhibited a more stellate shape and cytoplasm that was diffusely dark
brown when evaluated immunohistochemically. Similar findings were seen in the inguinal lymph
nodes and spleen of SHFV-inoculated patas and rhesus monkeys, although rounded macrophages
were detected in the spleen of one SHFV-inoculated patas monkey and inguinal lymph nodes of a
second SHFV-inoculated patas monkey. The macrophages appeared morphologically normal in all
mock-inoculated subjects.
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3.4. Viral RNA (vRNA) Replication Is Sustained in SHFV-Infected Patas Monkeys
SHFV-inoculated patas and rhesus monkeys had detectable viral RNA (vRNA) in the circulating
blood on day 2 PI (Figure 4A). The average peak titers in patas and rhesus monkeys were 6.75
(range 6.41–6.96) and 7.08 (range 6.79–7.36) log10 vRNA copies per mL, respectively. The patas
monkeys reached the peak vRNA copy number on day 4 PI, whereas the rhesus monkeys reached the
peak vRNA copy number between days 5 and 12 PI. In patas monkeys, vRNA copies were detectable
in all three subjects for the remainder of the experiment, except for days 15 and 19 PI when vRNA
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copy number was below the limit of detection in two subjects. The terminal vRNA copy number in
SHFV-inoculated patas monkeys was 3.42 (range 2.51–4.43) log10 vRNA copies per mL whole blood.
The terminal vRNA copy numbers in SHFV-inoculated rhesus monkeys was 6.30, 7.36, and 4.17 log10
vRNA copies per mL in the two non-survivors and single survivor, respectively. The correlation of
vRNA copies per mL with survival or clinical parameters is unwarranted due to the survival of 1 of
the SHFV-inoculated rhesus monkeys.
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Figure 3. Representative images showing liver immunohistochemistry staining of the indicated markers
for SHFV-inoculated rhesus (A) and patas (B) monkeys Scale bar represents 200 µm.
SHFV was detected by plaque assay in the axillary lymph node (n = 1), spleen (n = 1), and jejunum
(n = 1) of two SHFV-inoculated patas monkeys (Figure 4B). The highest titer was 3.36 log10 PFU/mg in
the jejunum of the SHFV-inoculated patas with the highest terminal vRNA copy number. In the two
non-surviving SHFV-inoculated rhesus monkeys, SHFV was found in the axillary and inguinal lymph
nodes (n = 2 and 1, respectively), spleen (n = 2), liver (n = 2), jejunum (n = 1), thyroid (n = 2), brain-stem
(n = 1), and kidneys (n = 2). Kidney tissue was the only tissue positive in all three SHFV-inoculated
rhesus monkeys. The highest tissue titer in SHFV-inoculated rhesus monkeys was 4.27 log10 PFU/mg
in the axillary lymph nodes. Plaque assays on whole blood were not performed due to experimental
sample requirements and blood collection volume limits.
The bone marrow, cerebella, jejuna, axial and inguinal lymph nodes, kidneys, and thyroids were
assessed for evidence of SHFV infection by transmission electron microscopy (TEM). Double membrane
vesicles (DMVs) and apparently mature virions were found in the jejunum of the SHFV-inoculated patas
monkey with the highest terminal vRNA copy number (Figure 4C,D). The livers of SHFV-inoculated
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patas monkeys were negative and were therefore not examined by TEM. ISH for SHFV vRNA
was performed to assess the cerebella, brainstems, spleens, livers and femoral bone marrow of
SHFV-inoculated subjects for signs of SHFV replication. The livers of two SHFV-inoculated patas
monkeys and, rarely, the spleen of the third were positive for SHFV vRNA (Figure 2B) using RNAscope.
The femoral bone marrow of the patas monkey with the highest terminal titer was positive for vRNA.
vRNA was detected by ISH in the cerebellum, brain-stem, spleen, and liver of all SHFV-inoculated
rhesus monkeys. vRNA was detected in femoral bone marrow of all three SHFV-inoculated rhesus
monkeys. Morphologically, ISH data support that monocytes and endothelial cells are sites of SHFV
infection in examined livers, spleens, brainstems, and cerebella of both SHFV-inoculated patas and
rhesus monkeys. In all tissues, cells positive for SHFV vRNA (RNAScope) were morphologically
consistent with macrophage-lineage cells. In each of the tissues evaluated, these cells were present in
fairly low numbers.
Viruses 2018, 10, x FOR PEER REVIEW  12 of 22 
 
inoculated patas monkey with the highest terminal vRNA copy number (Figure 4C,D). The livers of 
SHFV-inoculated patas monkeys were negative and were therefore not examined by TEM. ISH for 
SHFV vRNA was performed to assess the cerebella, brainstems, spleens, livers and fe oral bone 
marrow of SHFV-inoculated subjects for signs of SHFV replication. The livers of two SHFV-
inoculated patas monkeys and, rarely, the spleen of the third were positive for SHFV vRNA (Figure 
2B) using RNAscope. The femoral bone marrow of the patas monkey with the highest terminal titer 
was positive for vRNA. vRNA was detected by ISH in the cerebellum, brain-stem, spleen, and liver 
of all SHFV-inoculated rhesus monkeys. vRNA was detected in femoral bone marrow of all three 
SHFV-inoculated rhesus monkeys. Morphologically, ISH data support that monocytes and 
endothelial cells are sites of SHFV infection in examined livers, spleens, brainstems, and cerebella of 
both SHFV-inoculated patas and rhesus monkeys. In all tissues, cells positive for SHFV vRNA 
(RNAScope) were morphologically consistent with macrophage-lineage cells. In each of the tissues 
evaluated, these cells were present in fairly low numbers. 
 
Figure 4. Virological and microscopic evidence of SHFV replication in patas and rhesus monkeys. 
Mean vRNA copy number values in viral RNA copies per mL of whole blood for mock (open symbols) 
and SHFV-inoculated (closed symbols) patas monkeys (orange) and rhesus monkeys (blue) (A). The 
mean titer of tissues for SHFV-inoculated patas monkeys (orange) and rhesus monkeys (blue) in PFU 
per mg of 10% tissue homogenate of lymph nodes (LN), spleen, jejunum, cerebellum, and kidneys 
(B). Electron micrograph of jejunum from a SHFV-inoculated patas monkey showing double-
membrane vesicles (DMVs) and apparently mature virions (red box, C). Enlargement of boxed area 
from (C) showing apparently mature virions (yellow arrowheads) and double-membrane vesicles 
(yellow arrow) (D). The error bars represent standard deviation. 
Figure 4. Virological and microscopic evidence of SHFV replication in patas and rhesus monkeys. Mean
vRNA copy number values in viral RNA copies per mL of who e blood for mock (open symbols) and
SHFV-inoculated (closed symbols) patas monkeys (orange) and rhesus m nkeys (blue) (A). The ean
titer of tissues for SHFV-in culated patas monkeys (orange) d rhesus monkeys (blue) in PFU per mg
of 10% tissue homogenate of lymph nodes (LN), spleen, jejunum, c rebellum, and kidn s (B). Electron
micrograph of jejun m from a SHFV-inoculated patas monkey showi g double-membra e vesicles
(DMVs) and apparently mature virions (red box, C). Enlargement of boxed area from (C) showing
apparently mature virions (yellow arrowheads) and double-membrane vesicles (yellow arrow) (D).
The error bars represent standard deviation.
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3.5. SHFV Infection of Patas and Rhesus Monkeys Elicits Strong and Overlapping Immune Responses
Quantitative immunohistochemistry (qIHC) (Figure 5) revealed statistically significant (t-test,
p < 0.05) changes in inflammatory cell populations in the livers (Figure 3) of SHFV-inoculated monkeys
(Figure 5A). On average, SHFV-inoculated patas monkeys had livers with increased CD3 and Iba1
signals when compared to uninfected patas monkeys. CD8 signals were increased in the liver of
SHFV-inoculated patas monkeys when compared to uninfected patas monkeys, but the difference
did not reach significance (p = 0.06). CD8 and natural killer group protein 2a (NKG2A), a natural
killer (NK) cell marker, signals were increased in SHFV-inoculated rhesus monkeys compared to
uninfected controls. In the spleen, significant changes were seen in major histocompatibility complex
class-1 (MHC-1) and Iba1 signals between SHFV-inoculated and mock-inoculated patas monkeys
(Figure 5B). No significant differences in cell frequencies were observed for CD3, CD8, and NKG2A in
the splenic tissue of infected and uninfected patas monkeys. No significant changes were seen between
SHFV-inoculated and mock-inoculated rhesus monkey spleens for any of the markers quantified.
Analysis of plasma cytokine concentrations (Table 2) identified changes in both patas and rhesus
monkeys during SHFV infection. Interferon gamma (IFN-γ) concentrations in all SHFV-inoculated
patas monkeys were elevated on day 2 PI compared to the pre-exposure mean concentration
(group mean fold change (Figure 5D)). Later, IFN-γ concentrations decreased to baseline in two
SHFV-inoculated patas monkeys, whereas the concentration of the third patas monkey remained
elevated throughout the experiment with a second peak in concentration at 12 days PI. The two
non-surviving SHFV-inoculated rhesus monkeys had peak concentrations of similar magnitudes 2 days
PI, and all three subjects had increased concentrations by day 6 PI. The concentration of IL-2 (Figure 5E)
was significantly increased on day 2 PI in SHFV-inoculated rhesus monkeys. IL-10 concentrations
(Figure 5F) were significantly increased in the animals of both species on day 10 PI. IL-4 concentrations
(Figure 5H) were significantly decreased on days 2 and 4 PI. However, all SHFV-infected rhesus monkey
cytokine concentrations for these days were below the lower limit of detection. The SHFV-inoculated
patas monkeys had mild increases in interleukin 6 (IL-6) concentrations in comparison to their mock
counterparts but only significantly so on day 4 PI. SHFV-inoculated rhesus monkeys had increased IL-6
concentrations starting on day 2 PI, but these concentrations only reached statistical significance on day
8 PI (survivor) and terminal days (two non-survivors) (Figure 5I). Mean monocyte chemoattractant
protein 1 (MCP-1, Figure 5K) concentrations peaked at day 2 PI in all SHFV-inoculated patas monkeys
and the two non-surviving rhesus monkeys. All SHFV-inoculated rhesus monkeys had a second
MCP-1 concentration peak at day 8 PI. GM-CSF, IL-17, and IL-8 concentrations were not significantly
increased at any of the analyzed time points (Figure 5A,G,J, respectively).
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Rhesus-Mock −1 (−9–4) 12.88 (11.47–14.18) 0.73 (0.1–1.4) 0/3
Patas-Mock 3 (−9–10) 7.26 (4.21–11.62) 0.83 (0.1–2.39) 0/3
Rhesus-SHFV 3.67 (-6–15) 17.69 (5.71–34.58) 0.97 (0.05–2.15) 0/3
Patas-SHFV 14.34 (12–19) 53.96 (7.08–144.34) 12.37 (0.01–94.85) 0/3
IFNγ
Rhesus-Mock −0.34 (−9–6) 7.2 (5.51–8.99) 0.45 (0.05–0.89) 0/3
Patas-Mock 10.34 (6–15) 5.04 (3.87–6.3) 0.82 (0.12–2.8) 0/3
Rhesus-SHFV 5.34 (2–8) 121.72 (97.01–145.68) 8.45 (1.15–29.66) 0/3
Patas-SHFV 5.34 (2–12) 89 (70.41–122.97) 17.34 (0.45–80.81) 0/3
IL-2
Rhesus-Mock 6 (4–8) 11.03 (9.1–12.21) 0.52 (0.25–1.47) 0/3
Patas-Mock 3.67 (−6–15) 15.16 (7.79–21.71) 2.78 (0.77–10.43) 0/3
Rhesus-SHFV 3.67 (−6–15) 25.48 (24.5–27.41) 1.96 (0.22–7.49) 0/3
Patas-SHFV 15.34 (12–19) 51.96 (9.27–127.81) 14.64 (0.45–83.99) 0/3
IL-10
Rhesus-Mock −4.34 (−9–2) 49.02 (41.91–57.38) 2.35 (0.93–4.12) 0/3
Patas-Mock 11 (4–19) 57.66 (35.36–86.99) 10.42 (0.19–49.3) 1/3
Rhesus-SHFV 8.34 (6–11) 394.88 (149.65–522.9) 14.36 (2.01–57.89) 1/3
Patas-SHFV 9.34 (6–12) 515.1 (118.66–1240.73) 125.39 (1.1–815.32) 0/3
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Rhesus-Mock 5.34 (2–10) 7.64 (7.09–7.91) 0.55 (0.2–0.86) 1/3
Patas-Mock 15.34 (12–19) 6.37 (3.44–11.18) 1.25 (0.02–2.56) 1/3
Rhesus-SHFV 4 (2–8) 13.47 (3.69–22.07) 0.71 (0.21–1.6) 0/3
Patas-SHFV 9.34 (6–12) 23.04 (4.51–59.42) 5.31 (0.32–39.05) 0/3
IL-4
Rhesus-Mock 5.34 (2–8) 107.71 (100.81–117.81) 7.5 (3.13–14.18) 0/3
Patas-Mock 14.67 (10–19) 65 (51.98–75.98) 9.61 (0.75–29.45) 1/3
Rhesus-SHFV 8 (6–10) 85.2 (71.17–97.69) 6.4 (0.3–29.86) 0/3
Patas-SHFV 6 (−9–19) 167.85 (136.68–220.38) 33.54 (0.12–144.82) 0/3
IL-6
Rhesus-Mock 4.67 (2–8) 3.96 (3.65–4.5) 0.27 (0.03–0.45) 0/3
Patas-Mock 4.67 (−9–15) 6.25 (3.14–10.5) 1.07 (0.43–2.38) 0/3
Rhesus-SHFV 9 (8–11) 1765.16 (20.34–5212.14) 19.84 (0.79–322.88) 1/3
Patas-SHFV 7.67 (2–15) 22.41 (18.46–28.86) 5.27 (0.21–18.96) 0/3
IL-8
Rhesus-Mock −3.34 (−6–2) 1062.94 (440.5–1640.1) 30.11 (5.28–112.68) 0/3
Patas-Mock −3.67 (−9–4) 556.13 (1.53–1640.1) 7.95 (0–103.88) 0/3
Rhesus-SHFV 5 (2–11) 1520.19 (610.34–2102) 59.82 (10.78–564.94) 1/3
Patas-SHFV 15 (12–21) 4.53 (2.3–8.99) 0.92 (0.01–5.91) 1/3
MCP-1
Rhesus-Mock 2 (−6–8) 237.47 (204.28–294.46) 21 (13.69–27.62) 0/3
Patas-Mock 2 (−6–8) 2681.4 (459.13–6776.22) 132.74 (34.86–458.34) 0/3
Rhesus-SHFV 6 (2–8) 10549.99 (7716.58–13654.57) 503.84 (102.16–2358.69) 0/3
Patas-SHFV 2 (2–2) 11477.69 (5959.96–15828.29) 1074.52 (85.91–5030.32) 0/3
Flow cytometry of whole blood revealed that CD4+ T-cells were decreased in SHFV-inoculated
patas monkeys on days 2–8 and day 15 PI. CD4+ T-cell numbers did not significantly changed
in SHFV-inoculated rhesus monkeys (Figure 6A). CD8+ T-cell numbers were decreased in both
SHFV-inoculated patas and rhesus monkeys (days 2–8 and days 2, 6 PI, respectively) (Figure 6B).
Increased frequency of circulating NK cells were observed in SHFV-inoculated patas monkeys on
day 19 PI (Figure 6C). In contrast, SHFV-inoculated rhesus monkeys had a single, larger, increase
in circulating NK cells on days 8 to 10 PI. The changes in Ki67+ NK cells in SHFV-inoculated patas
monkeys were more variable, with one patas monkey reaching peak frequency at day 2 PI and the
other two patas monkeys reaching peak frequency at day 8 PI (Figure 6D). Ki-67+ NK cells were
significantly increased only in SHFV-infected rhesus monkeys on day 8 PI.
Circulating CD14+ monocytes (Figure 6E) were decreased in SHFV-inoculated patas monkeys
at day 2 PI prior to returning to baseline frequency, whereas frequency of these monocytes in
SHFV-inoculated rhesus monkeys appeared unchanged throughout the experiment, excluding a
small, but significant, increase on day 10 PI (Figure 6E). SHFV-inoculated patas and rhesus monkeys
had decreased frequency of CD14+ CD163+ macrophages (Figure 6F) on days 6–8 PI and 2–10 PI,
respectively, and these numbers remained unchanged until each subject’s respective endpoint.
The numbers of PD-1+ CD8+ T-cells began to increase in both SHFV-inoculated patas and rhesus
monkeys on days 10–19 and 8–10 PI, respectively (Figure 6G). Ki-67+ CD8+ T-cell frequency was
elevated in SHFV-inoculated patas monkeys from days 2–19 PI with the exception of day 10 PI
(Figure 6H). In SHFV-inoculated rhesus monkeys, Ki-67+ CD8+ T-cells were elevated on days 2 and
8 PI.
IgG antibody responses were detected by enzyme-linked immunosorbent assay (ELISA) in all
three SHFV-inoculated patas monkeys and two of the three (the survivor and one non-survivor)
SHFV-inoculated rhesus monkeys (Figure 7). Two SHFV-inoculated patas monkeys had detectable
anti-SHFV antibodies on day 10 PI and the third monkey on day 15 PI. Two of three SHFV-inoculated
rhesus monkeys mounted antibody responses by day 10 PI. The response magnitude continued to
increase in all responding subjects until their respective endpoints. Anti-SHFV antibodies were not
detected in mock-inoculated subjects at any time.
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bars represent standard deviation. * symbols represent p < 0.05 and are colored according to species.
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4. Discussion
The goal of this experiment was to characterize and compare SHFV infection of patas and
rhesus monkeys to assess the usefulness of comparing biologically similar refractory and susceptible
primate species in hemorrhagic fever virus infection. This is the first report of successful experimental
SHFV infection of patas monkeys. Our data demonstrate that SHFV can replicate to high titers in
patas monkeys without causing significant disease. The disease observed in SHFV-inoculated patas
monkeys is a mild clinical disease characterized by changes in serum chemistry and circulating blood
populations, with transient lymphadenopathy being the only outward sign of infection.
Consistent with previously obtained data derived from experimentally SHFV-infected
macaques [10,13,14], ISH and electron microscopy of the infected tissues indicate that tissue-resident
macrophages and endothelial cells are likely the main targets of SHFV in patas monkeys. Together,
these data suggest that SHFV targets the same cell types in cercopithecines. Although the vRNA
copy number peaked earlier in patas monkeys, the peak viral loads were largely similar between all
monkeys. In rhesus monkeys and Japanese acaques, the day of peak SHFV titer is highly variable
and does not correlate with survival [13,14]. These results suggest that the timing and magnitude of
viral load is unlikely to have significant impacts on disease course, although additional studies would
be required to fully characterize the relationship between disease phenotype and viral replication
dynamics in monkeys of each species.
Given the extreme differences in disease course and outcomes during SHFV infection in patas
and rhesus monkeys, the relatively high degree of overlap in host-response features was unexpected.
Changes in IFN-γ and MCP-1 concentrations, and circulating macrophage, NK, and T-cell populations,
were similar between SHFV-inoculated patas and rhesus monkeys. However, patas monkeys did not
respond with large IL-6 concentration increases observed in both this experiment’s rhesus monkeys
and in other experimental work [10,13,14]. This difference is of particular interest as IL-6 has been
associated with non-survival in SHFV-infected rhesus monkeys, and because decreased concentrations
of IL-6 were seen in in vitro infection of monocyte-derived macrophages and dendritic cells from
baboons [13,15]. Given the potential role of IL-6 in human VHFs, our odel offers an opportunity to
explore the potential of therapies, such as neutralizing antibodies, aimed at modulating IL-6 responses
during infection [26,27].
Although animals of both species showed decreases in CD8+ T-cell frequency early in infection,
with an increase in PD1+ CD8+ T-cell frequency later in infection, only SHFV-infected patas monkeys
showed an increase in CD4+ T-cell numbers largely throughout infection. Additional cell types
or circulating factors not covered in this experiment may be present in monkeys of either species
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during SHFV infection. Future experiments are required to further define the function and activation
state of T and NK cells in monkeys of both species. Functional differences among cell types and
circulating factors between patas and rhesus monkeys may also play a role and could be the subject of
further experiments.
Although similarities in circulating cell populations were observed in monkeys of both species,
significant differences in tissue immune cells were observed. The livers of SHFV-inoculated patas
monkeys had increased CD3 and Iba1 IHC signals, whereas those of SHFV-inoculated rhesus monkeys
had elevated CD8 and NKG2A IHC signals. Increases in CD8 and NKG2A signals in the absence of an
increase in the CD3 signal suggests that SHFV infection leads to an increase in infiltrating NK cells in
rhesus monkeys [28]. Indeed, the frequency of circulating NK cells were elevated at days 8 and 10 PI
in rhesus monkeys. The data suggest that a potent type 1 IFN response occurs in SHFV-inoculated
rhesus monkeys, but whether a similar response is present in SHFV-inoculated patas monkeys is
unclear. NK cell responses are important for survival in human Ebola virus disease cases [29,30].
Differences in the timing of NK cell responses are also a key difference in non-lethal, mild disease and
lethal, severe Lassa virus infections in macaques [31], suggesting the species-specific NK cell responses
observed here warrant further exploration. For comparison, and as described in the recent paper by
Buechler et al. [11], olive baboons and rhesus monkeys infected with the SHFV-related Southwest
baboon virus 1 (SWBV-1) also developed increases in NK and CD8+ T-cell numbers, with CD8+ T-cell
frequency remained elevated throughout the observation period. Infected olive baboons and surviving
rhesus monkeys had less prominent NK cell increases compared to the non-surviving rhesus monkeys.
NK cell dynamics suggest a short-lived peak in olive baboons and rhesus monkeys that did not develop
severe disease due to SWBV-1 infection. Together, these data support a role for appropriate timing
and activation of NK cells in modulating disease presentation in VHFs. While standard ELISA assays
are unable to distinguish between neutralizing and non-neutralizing antibodies, recent work has
demonstrated that non-neutralizing antibodies are required for protection against Lassa virus and
can be used as part of antibody cocktails in treating Ebola virus infections [32,33]. Additional work is
required to further characterize the role and importance of anti-SHFV antibodies in both patas and
rhesus monkeys.
Increased detection of Iba1, a macrophage marker, suggests that SHFV infection leads to an
increase in the number of macrophages in the liver [34]. Determining the sources and function of
these additional liver macrophages in SHFV-inoculated patas monkeys is important given the changes
in MCP-1 and IL-6 concentrations and the differential roles of hepatic resident and non-resident
macrophages [35–38]. SHVF is dependent on CD163 for cellular entry [39], and preferential targeting
of CD163+ cells by SHFV may explain why both patas and rhesus monkeys lost CD163+ macrophages.
CD163 is associated with alternatively-polarized macrophages, and macrophage polarization plays
a significant role in immunity and infection [40–42]. The presence of rounded and vacuolated
macrophages in the livers of SHFV-inoculated rhesus monkeys but not in their patas counter parts
suggests that a species-specific macrophage function may play a key role in SHFV pathogenesis.
Rather than a “cytokine storm”, we propose that a process driven by NK cells and macrophages is
the deciding factor in developing hemorrhagic fever. The lack of massive differences in host response
to SHFV infection in each species suggests that a relatively small subset of the host response has the
potential to avoid or cause hemorrhagic fever during viral infection. Similar results have been observed
when comparing hemorrhagic and non-hemorrhagic variants of lymphocytic choriomeningitis virus
(LCMV) in rhesus monkeys. Additionally, hemorrhagic LCMV infections in rhesus monkeys share
features with SHFV infections in rhesus monkeys, such as increased IL-6 concentrations and an early
peak in NK cells [43–45]. Both variants of LCMV induced strong host responses, but only a small
number of differentially expressed genes were identified between hemorrhagic and non-hemorrhagic
infections [45,46]. This work with LCMV and our work suggest that viral hemorrhagic fevers may be
initiated by relatively small components of the host’s response to infection. As such, the comparison of
SHFV infection in patas and rhesus monkeys offers a useful tool to characterize mechanisms involved
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in developing hemorrhagic fevers and exploring or developing therapies to treat human disease.
SHFV infection in patas and rhesus monkeys could be used as a tool to explore the use of neutralizing
antibodies that target immune system components, both to develop therapies and further characterize
mechanisms of disease.
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